Pharmacelera raises €6M to expand in U.S. and build out its high speed, high accuracy, deep tech drug discovery platform

Core Insights - Pharmacelera has raised €6 million to expand its operations in the U.S. and enhance its drug discovery platform utilizing Quantum Mechanics and Artificial Intelligence [1] - The funding round was led by Heran Partners and included participation from Clave Capital, Inveready, and Bio&Tech Smart Capital [1] - The company's proprietary QaiM technology can identify novel molecular candidates up to 10 times better and 75,000 times faster than traditional AI methods [1] Company Overview - Pharmacelera is a deep tech company focused on revolutionizing drug discovery through advanced algorithms that explore a vast chemical space [1] - The company has participated in over 100 projects, achieving notable successes in GPCRs and securing repeat business from major pharmaceutical companies [1] - Founded by experts in AI and drug discovery, Pharmacelera's team has co-authored over 500 publications and holds more than 50 patents [1] Investment and Growth Strategy - The recent investment will facilitate the establishment of a permanent team in the U.S. and expand the technical capabilities of its QaiM engine [1] - The funding follows a strategic alliance with General Inception, enhancing Pharmacelera's technology and intellectual property for several portfolio companies [1] - Investors have expressed strong confidence in Pharmacelera's technology, citing its potential to significantly impact drug discovery processes [1]